European Heart Journal

Papers
(The H4-Index of European Heart Journal is 96. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure5667
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)5245
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation2803
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice2572
2021 ESC/EACTS Guidelines for the management of valvular heart disease2175
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension1115
2020 ESC Guidelines for the management of adult congenital heart disease949
2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy884
2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death813
2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease806
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the Internatio767
COVID-19 is, in the end, an endothelial disease679
Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era655
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe494
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases473
2023 ESC Guidelines for the management of acute coronary syndromes417
Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy408
An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcircula396
European Society of Cardiology: cardiovascular disease statistics 2021364
Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors364
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis360
Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019353
Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study348
Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research341
2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery326
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement321
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Ather318
Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus316
Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study287
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure279
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force278
Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance271
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine258
Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial257
The ‘Ten Commandments’ for the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation250
C-reactive protein and clinical outcomes in patients with COVID-19249
2023 ESC Guidelines for the management of cardiomyopathies229
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement220
SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions210
Pulmonary embolism in COVID-19 patients: a French multicentre cohort study197
Effects of tobacco cigarettes, e-cigarettes, and waterpipe smoking on endothelial function and clinical outcomes193
Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study190
Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyc186
Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure o182
COVID-19 kills at home: the close relationship between the epidemic and the increase of out-of-hospital cardiac arrests179
Left bundle branch area pacing outcomes: the multicentre European MELOS study175
Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)171
2023 ESC Guidelines for the management of endocarditis168
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation and coexistent atrial fibrillation – Dual versus triple antithrombotic therapy165
The neutrophil–lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials162
Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement160
Prevalence of statin intolerance: a meta-analysis158
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)155
Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies154
Isolated tricuspid valve surgery: impact of aetiology and clinical presentation on outcomes150
Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction149
Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study144
A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial143
Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists141
The Mediterranean diet, plasma metabolome, and cardiovascular disease risk141
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes139
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)138
The ESC Clinical Practice Guidelines for the Management of Adult Congenital Heart Disease 2020132
The physical activity paradox in cardiovascular disease and all-cause mortality: the contemporary Copenhagen General Population Study with 104 046 adults131
Heart failure drug treatment: the fantastic four131
Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT–FFR trial125
Multicentre, randomized comparison of two-stent and provisional stenting techniques in patients with complex coronary bifurcation lesions: the DEFINITION II trial124
Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis123
Associations between gut microbiota, faecal short-chain fatty acids, and blood pressure across ethnic groups: the HELIUS study123
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF122
Association between adiposity and cardiovascular outcomes: an umbrella review and meta-analysis of observational and Mendelian randomization studies122
Joint exposure to various ambient air pollutants and incident heart failure: a prospective analysis in UK Biobank122
TRI-SCORE: a new risk score for in-hospital mortality prediction after isolated tricuspid valve surgery121
Causal associations of short and long sleep durations with 12 cardiovascular diseases: linear and nonlinear Mendelian randomization analyses in UK Biobank121
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial120
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes120
The European bifurcation club Left Main Coronary Stent study: a randomized comparison of stepwise provisional vs. systematic dual stenting strategies (EBC MAIN)119
Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism119
Genome-wide analysis identifies novel susceptibility loci for myocardial infarction119
Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials118
AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial115
Multi-organ assessment in mainly non-hospitalized individuals after SARS-CoV-2 infection: The Hamburg City Health Study COVID programme113
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial113
Lifestyle, cardiometabolic disease, and multimorbidity in a prospective Chinese study111
Empagliflozin in acute myocardial infarction: the EMMY trial106
Non-linear Mendelian randomization analyses support a role for vitamin D deficiency in cardiovascular disease risk105
Application of artificial intelligence to the electrocardiogram103
Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial102
Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake102
Electrocardiogram screening for aortic valve stenosis using artificial intelligence99
Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis98
Vulnerable plaques and patients: state-of-the-art98
Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry97
Efficacy of a digital therapeutics system in the management of essential hypertension: the HERB-DH1 pivotal trial96
The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study96
EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic96
0.060230016708374